Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration this week approved a new personalized, oral drug for a molecularly defined subset of chronic lymphocytic leukemia (CLL) patients who have relapsed or are refractory to chemotherapy.

Venclexta (venetoclax), which AbbVie developed and markets with Genentech in the US, targets B-cell lymphoma 2, a commonly overexpressed protein known to drive cancer in CLL patients. The agency approved the drug for patients who have received prior therapy and have a 17p deletion as detected by Abbott Molecular's Vysis CLL FISH probe kit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.